<ѻý>FDA Warns on Using Surgical Device for Aesthetic Skin Proceduresѻý> Agency details potentially life-threatening adverse events with plasma-generating device Mar 14, 2022
<ѻý>Novel Therapies Active in Head and Neck Cancersѻý> High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<ѻý>Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancersѻý> 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
<ѻý>Predicting Treatment Response in Inflammatory Muscle Disordersѻý> Swedish registry study elicits factors associated with improvement Feb 16, 2022
<ѻý>Acute Muscle Weakness and Skin Rash Following a Lupus Diagnosisѻý> Clinicians consider many differentials Feb 14, 2022
<ѻý>Two Years On, Tremfya Still Shines in Psoriatic Arthritisѻý> Efficacy increases in long-term extension data Feb 10, 2022
<ѻý>Hair Loss Drugs Ranked in Order of Efficacyѻý> Meta-analysis attempts a head-to-head comparison Feb 07, 2022
<ѻý>Evidence Begins to Gel for Atopic Dermatitis, Multiple Comorbid Conditionsѻý> Atopic, metabolic, cardiovascular, and mental health conditions cited in guideline update Feb 02, 2022
<ѻý>Six Medical ѻý With the Highest Hourly Wagesѻý> Plastic and orthopedic surgery top the list Jan 27, 2022
<ѻý>Psoriasis Patients, Docs Want to Do More to Prevent Heart Problemsѻý> Despite well-known cardiovascular risks, most patients currently undertreated Jan 19, 2022
<ѻý>FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitisѻý> Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market Jan 18, 2022
<ѻý>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Upѻý> More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<ѻý>Melanoma Patient on Immunotherapy Develops Severe Dermatitisѻý> Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<ѻý>IL-13 Inhibitor Approved for Adults With Atopic Dermatitisѻý> Significantly greater lesion clearance with tralokinumab in placebo-controlled studies Dec 28, 2021
<ѻý>Doc Fired After Standing Up to Private Equity; RFK Jr.'s Anti-Vax Machineѻý> This past week in healthcare investigations Dec 22, 2021
<ѻý>Long-Term Data Reinforce Standard of Care in Unresectable Melanomaѻý> Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
<ѻý>Think TikTok Is Smarter Than Me? Then I'm Not the Right Doctor for Youѻý> Modern times have fundamentally altered the landscape of healthcare Nov 30, 2021
<ѻý>Signs of Relief From 'Therapeutic Drought' in Atopic Dermatitisѻý> Encouraging results from pipeline agents targeting Tѻý-specific inflammation Nov 09, 2021
<ѻý>Could This Biologic Drug Work in Patients Lacking Its Target?ѻý> Bizarre finding with omalizumab Nov 07, 2021
<ѻý>Dramatic Responses in Cutaneous Sarcoidosis With JAK Inhibitorѻý> More than 80% reduction in disease activity in case series of tofacitinib treatment Nov 07, 2021
<ѻý>Substantial Improvement in Vitiligo With Topical JAK Inhibitorѻý> About 30% of patients had 75% clearance after 6 months, half had 50% clearance Nov 06, 2021
<ѻý>Early Success With New Target in Atopic Dermatitisѻý> Inhibition of Tѻý-related inflammation leads to rapid improvement in disease activity Nov 05, 2021
<ѻý>Topical PDE4 Inhibitor Impresses in Trial of Seborrheic Dermatitisѻý> Rapid, persistent improvement in body surface area, itch, other symptoms with roflumilast Nov 04, 2021
<ѻý>How Should Patients With Autoimmune Diseases Approach COVID Vaccination?ѻý> Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
<ѻý>Botox Doc's License Suspended Over Breast, Penis Enhancement Harmsѻý> One patient allegedly required two surgeries to fix penile enhancement gone wrong Oct 21, 2021
<ѻý>FDA to Make Isotretinoin Prescribing Gender Neutralѻý> Revision to risk management program dissociates gender from reproductive categories Oct 18, 2021
<ѻý>Is Private Equity a Dangerous Employer?ѻý> Firms' investments in healthcare continue to expand, at what cost? Oct 14, 2021
<ѻý>Case: VEGFR Inhibition in Merkel Cell Carcinoma Patientѻý> Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
<ѻý>FDA Warns on Needle-Free Injection Devices for Facial Fillersѻý> Serious injuries and "irreversible" harm to skin, lips, and eyes reported with unapproved devices Oct 08, 2021
<ѻý>FDA Issues Orders Clarifying Rules for Marketing Sunscreensѻý> But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
<ѻý>In RA, Little Risk for Recurrent Cancer With Biologic Treatmentѻý> Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<ѻý>FDA Approves First Topical JAK Inhibitor for Atopic Dermatitisѻý> Significant skin clearance, reduced itch in majority of patients treated with ruxolitinib cream Sep 22, 2021
<ѻý>Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanomaѻý> Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
<ѻý>What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor?ѻý> Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
<ѻý>Oral Drug Active in Teens With Atopic Dermatitisѻý> Significant improvement at 12 weeks in 42-46% by one index, 68-72% by another Aug 24, 2021
<ѻý>Dual IL-17 Inhibitor Achieves Deep Responses in Hidradenitis Suppurativaѻý> Bimekizumab outclasses placebo, compares favorably with adalimumab Aug 20, 2021
<ѻý>Adalimumab Adds to Surgery Benefits for Hidradenitis Suppurativaѻý> Significantly higher response rates before and after surgery with biologic agent Aug 18, 2021
<ѻý>JAK Inhibitor Tops Mab for Eczemaѻý> New disease-modifying treatment option on the horizon Aug 04, 2021
<ѻý>Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too!ѻý> A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021